Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Apelin in preparation of medicine for treating silicosis

A drug and pharmaceutical technology, applied in the field of pharmaceutically active peptides, achieves the effects of good safety, alleviating fibrosis symptoms, and reducing expression levels

Pending Publication Date: 2022-03-01
广东省职业病防治院 +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] It is known that a variety of lung-related diseases may cause pulmonary fibrosis, but the pathogenesis and pathogenesis of different lung-related diseases are different. Although Apelin can improve the pulmonary fibrosis caused by BPD, but Whether it also works well for other types of lung disease is unknown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Apelin in preparation of medicine for treating silicosis
  • Application of Apelin in preparation of medicine for treating silicosis
  • Application of Apelin in preparation of medicine for treating silicosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Embodiment 1: Therapeutic effect of Apelin on mouse silicosis

[0027] SPF grade C57BL / 6 male mice (6-8 weeks old, body weight 18-25g) were selected, randomly divided into 3 groups (15 mice in each group), and the control group, silicosis group and silicosis + Apelin treatment were respectively set up by the following methods Group.

[0028] Control group: Inject 20 μL of normal saline through the mouse trachea;

[0029] Silicosis group: Inject 20 μL of 250 g / L silica suspension through the trachea of ​​mice by tracheal exposure method;

[0030] Silicosis + Apelin treatment group: Inject 20 μL of 250 g / L silica suspension through the trachea of ​​mice by the tracheal exposure method. From the 3rd day after modeling, mice in this treatment group were intraperitoneally injected with 500 μg / kg of Apelin-13 trifluoroacetate (purchased from Germany sigma company).

[0031] After the above-mentioned groups were set up, conventional animal feeding was carried out; 5 mice in...

Embodiment 2

[0037] Embodiment 2: the influence of different concentrations of Apelin on A549 cytotoxicity

[0038] Control group: A549 cells (human lung cancer cells) were cultured in serum-free GIBCO DMEM high-glucose medium (purchased from Thermo Scientific, USA);

[0039]Apelin administration group: A549 cells (human lung cancer cells) were cultured in serum-free GIBCO DMEM high-glucose medium containing Apelin (Apelin-13 trifluoroacetate) at concentrations of 1, 0.1, 0.01, 0.001, and 0.0001 μM middle.

[0040] After the control group and the Apelin-administered group were placed in a constant temperature incubator for 48 hours, the toxic effects of Apelin at various concentrations on A549 were detected using the CCK-8 kit. Test results such as image 3 Shown: Compared with the control group, Apelin at 0.0001, 0.001, 0.01, and 0.1 μM has no obvious toxic effect on A549 cells.

Embodiment 3

[0041] Example 3: Effect of Apelin on expression level of epithelial-mesenchymal transition (EMT) marker protein regulated by silicon dioxide Control group: A549 cells (human lung cancer cells) were cultured in serum-free medium;

[0042] Silica exposure group: A549 cells (human lung cancer cells) were cultured in serum-free medium containing silica at a concentration of 100 μg / mL;

[0043] Apelin+silica exposure group: A549 cells (human lung cancer cells) were cultured in serum-free GIBCODMEM containing 100 μg / mL silica and 0.1, 1 μM Apelin (Apelin-13 trifluoroacetate) in high glucose medium.

[0044] The above groups were placed in a constant temperature incubator for 48 hours, and the changes in the protein levels of epithelial-mesenchymal transition (EMT) markers were detected by Western blotting. The detection results were as follows: Figure 4 shown.

[0045] Figure 4 The results showed that: compared with the control group, the protein expression of the epithelial m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of active peptides of medicines, and discloses application of Apelin in preparation of medicines for treating silicosis. Tests show that Apelin has a good curative effect on relieving diseases of silicosis, has a good medicinal value prospect, and can be developed into a novel medicine for treating silicosis.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutically active peptides, and in particular relates to the application of Apelin in the preparation of medicines for treating silicosis. Background technique [0002] Apelin (Apelin / APLN) is a biologically active peptide, which was first isolated, extracted, purified and named from the gastric secretion of cattle in 1998. The human Apelin gene is located on the X chromosome, and its precursor peptide consists of 77 active amino acid residues, which can be cut into active peptide molecular fragments of different lengths by proteolytic enzymes, among which Apelin-13 and [Pyr1]Apelin- 13 is the most common subtype in human plasma, and its receptor is G protein-coupled receptor-angiotensin Ⅰ type 1 receptor-related protein. [0003] In recent years, it has been found that injection of Apelin can reduce the bronchopulmonary dysplasia and pulmonary fibrosis of neonatal rats exposed to hyperoxia, reduce...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/10A61P11/00
CPCA61K38/10A61P11/00
Inventor 赵娜黄永顺瞿红鹰
Owner 广东省职业病防治院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com